论文部分内容阅读
肥胖不仅是T2DM的发病危险因素之一,且在已患有T2DM的患者中,超重或肥胖可明显增加其并发症的发生风险。因此,有效的体重管理不仅可改善血糖控制,同时有可能减少大血管和微血管并发症的发生风险。基于肠促胰素治疗的利拉鲁肽,在降低血糖的同时有效控制体重,为超重或肥胖T2DM患者提供了更好的选择。本文就T2DM患者体重管理的重要性及利拉鲁肽在体重管理方面的优势进行综述。
Obesity is not only one of the risk factors of T2DM, but also the overweight or obesity significantly increases the risk of complications in patients with T2DM. Therefore, effective weight management not only improves glycemic control, but also reduces the risk of macrovascular and microvascular complications. Liraglutide, which is based on incretin therapy, effectively controls body weight while lowering blood glucose, providing a better alternative for overweight or obese T2DM. This article reviews the importance of weight management in patients with T2DM and the benefits of liraglutide in weight management.